Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency

Next Previous
Trial Profile

A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avalotcagene ontaparvovec (Primary) ; Prednisolone; Prednisone
  • Indications Ornithine carbamoyltransferase deficiency disease
  • Focus Adverse reactions; First in man
  • Acronyms CAPtivate
  • Sponsors Dimension Therapeutics; Ultragenyx Pharmaceutical

Most Recent Events

  • 03 Jan 2022 Status changed from active, no longer recruiting to completed.
  • 29 Nov 2021 Results presented in an Ultragenyx Pharmaceutical media release.
  • 29 Nov 2021 According to Ultragenyx Pharmaceutical media release, new long-term data from this study were presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top